Decreased apolipoprotein A-I level indicates poor prognosis in extranodal natural killer/T-cell lymphoma, nasal type
Open Access
- 1 March 2016
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 9, 1281-1290
Abstract
Background: Extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTL) is an invasive lymphoid malignancy with unfavorable survival, for which a prognostic model has not yet been validated. We hypothesized that serum apolipoprotein A-I (ApoA-I) may serve as a novel prognostic marker for ENKTL. Patients and methods: A total of 236 newly diagnosed cases of ENKTL were analyzed retrospectively. Results: The optimal cutoff value for the serum ApoA-I level was determined to be 0.95 g/L. A total of 154 and 82 cases were assigned to the high and low ApoA-I groups, respectively. Patients in the low ApoA-I group tended to present with poorer clinical features, a lower complete remission rate (P=0.001), and poor median progression-free survival (PPPPConclusion: Our results showed that the baseline serum ApoA-I level was helpful for predicting ENKTL prognosis.Keywords
This publication has 44 references indexed in Scilit:
- Hepatitis B virus infection correlates with poor prognosis of extranodal natural killer/T cell lymphomaLeukemia & Lymphoma, 2014
- Faculty Opinions recommendation of Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.2013
- Fasting blood glucose is a novel prognostic indicator for extranodal natural killer/T-cell lymphoma, nasal typeBritish Journal of Cancer, 2013
- Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group StudyJournal of Clinical Oncology, 2011
- Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma StudyJournal of Clinical Oncology, 2009
- Validation of serum biomarkers for detection of early-stage ovarian cancerAmerican Journal of Obstetrics and Gynecology, 2009
- Extranodal nasal type NK/T-cell Lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapyEuropean Journal of Cancer, 2005
- Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patientsBlood, 2004
- Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic IndexBlood, 2004
- Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's LymphomasJournal of Clinical Oncology, 1999